Arcus Biosciences Announces New Employment Inducement Grants

first_img Twitter Arcus Biosciences Announces New Employment Inducement Grants Local NewsBusiness By Digital AIM Web Support – February 9, 2021 WhatsApp Facebook Twitter HAYWARD, Calif.–(BUSINESS WIRE)–Feb 9, 2021– Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 126,200 shares of the Company’s common stock at an exercise price per share of $41.39, which was the closing price on February 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcus Biosciences Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A 2a /A 2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. In addition, domvanalimab is advancing into ARC-10, Arcus’s “two in one trial” to support the potential approvals of both zimberelimab and zimberelimab + domvanalimab and a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage III NSCLC setting. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com. Inducement PR Source: Arcus Biosciences View source version on businesswire.com:https://www.businesswire.com/news/home/20210209005848/en/ CONTACT: Katherine Bock VP Investor Relations & Corporate Strategy (510) 694-6231 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: Arcus Biosciences, Inc. Copyright Business Wire 2021. PUB: 02/09/2021 04:10 PM/DISC: 02/09/2021 04:11 PM http://www.businesswire.com/news/home/20210209005848/encenter_img Previous articleBlue Jackets C Mikko Koivu retires during 16th NHL seasonNext articlePrimerica Reports Fourth Quarter 2020 Results Digital AIM Web Support TAGS  WhatsApp Facebook Pinterest Pinterestlast_img